IP Library Granted Patent US 7,771,760
Granted Patent B2
US 7,771,760 · App. 11/394,495 · Granted Aug 10, 2010

Oils of capsaicinoids and methods of making and using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,771,760
App. No.
11/394,495
Granted
Aug 10, 2010
Kind
B2
Abstract

Oils of capsaicinoids and methods of making and using them are described. In some variations, the oils of capsaicinoids comprise at least 40% w/w capsaicinoid and a solvent capable of solubilizing the capsaicinoid, wherein the oil of capsaicinoid is substantially free of capsaicinoid crystals or capsaicinoid precipitates. In other variations, the oils of capsaicinoids consist essentially of at least 40% w/w capsaicinoid and a solvent capable of solubilizing the capsaicinoid. The solvent may be a semi-volatile solvent, a non-volatile solvent, or a volatile solvent, and the oil may comprise at least 50% w/w capsaicinoid, 60% w/w capsaicinoid, 70% w/w capsaicinoid, 80% w/w capsaicinoid, 90% w/w capsaicinoid, or 95% w/w capsaicinoid. The oil of capsaicinoid may also include a crystallization inhibitor.

Claims (32)

1. A topical oil in unit dosage form comprising:

at least 40% w/w of a capsaicinoid;

a solvent capable of solubilizing the capsaicinoid; and

a capsaicinoid crystallization inhibitor, wherein the oil is stable at room temperature and is substantially free of capsaicinoid crystals or capsaicinoid precipitates.

2. The oil of claim 1 wherein the capsaicinoid crystallization inhibitor is polyvinylpyrrolidone.

3. The oil of claim 1 wherein the solvent has a molecular weight of about 100 to about 300 Daltons and a boiling point above about 69° C.

4. The oil of claim 1 wherein the solvent is a semi-volatile solvent.

5. The oil of claim 4 wherein the solvent is selected from the group consisting of terpenes, tea tree oils, essential oils, and mixtures thereof.

6. The oil of claim 1 wherein the solvent is a non-volatile solvent.

7. The oil of claim 6 wherein the non-volatile solvent is selected from the group consisting of polyethylene glycol, propylene glycol, tetrahydrofurfuryl alcohol polyethyleneglycol ether, diethylene glycol monoethyl ether, benzyl alcohol and mixtures thereof.

8. The oil of claim 1 wherein the solvent is a volatile solvent.

9. The oil of claim 8 wherein the volatile solvent is selected from the group consisting of methanol, ethanol, isopropyl alcohol, and mixtures thereof.

10. The oil of claim 1 wherein the capsaicinoid is capsaicin and wherein the oil comprises at least 50% w/w capsaicin.

11. The oil of claim 1 wherein the capsaicinoid is capsaicin and wherein the oil comprises at least 60% w/w capsaicin.

12. The oil of claim 1 wherein the capsaicinoid is capsaicin and wherein the oil comprises at least 70% w/w capsaicin.

13. The oil of claim 1 wherein the capsaicinoid is capsaicin and wherein the oil comprises at least 80% w/w capsaicin.

14. The oil of claim 1 wherein the capsaicinoid is capsaicin and wherein the oil comprises at least 90% w/w capsaicin.

15. The oil of claim 1 wherein the capsaicinoid is capsaicin and wherein the oil comprises at least 95% w/w capsaicin.

16. The oil of claim 1 where the capsaicinoid is capsaicin.

17. A method of treating a capsaicinoid-responsive condition in a subject comprising administering the oil of claim 1 .

18. The method of claim 17 wherein the oil is applied topically to the skin or a mucous membrane of the subject.

19. The method of claim 18 wherein the oil is applied for at least about 10 minutes.

20. The method of claim 18 wherein the oil is applied for at least about 30 minutes.

21. The method of claim 18 wherein the oil is applied for at least about one hour.

22. The method of claim 18 further comprising removing the oil with a cleansing gel.

23. A method for making a topical oil in unit dosage form comprising the steps of:

solubilizing at least 40% w/w capsaicin in a volatile or semi-volatile solvent;

adding a capsaicin crystallization inhibitor; and

removing substantially all of the volatile or non-volatile solvent, wherein the oil is stable at room temperature.

24. The method of claim 23 wherein the capsaicin crystallization inhibitor is polyvinylpyrrolidone.

25. The method of claim 23 wherein the solvent is a volatile solvent selected from the group consisting of ethanol, isopropyl alcohol, and mixtures thereof.

26. The method of claim 23 wherein the solvent is a semi-volatile solvent selected from the group consisting of terpenes, tea tree oils, essential oils, and mixtures thereof.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2019
From: ACORDA THERAPEUTICS, INC.
To: GRÜNENTHAL GMBH
Reel/Frame 049260/0707 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2018
From: NEUROGESX, INC.
To: ACORDA THERAPEUTICS, INC.
Reel/Frame 045515/0320 →
RELEASE OF SECURITY INTEREST Recorded May 31, 2017
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NEURONEX, INC.; CIVITAS THERAPEUTICS, INC.; ACORDA THERAPEUTICS, INC.
Reel/Frame 042643/0878 →
SECURITY INTEREST Recorded Jun 10, 2016
From: ACORDA THERAPEUTICS, INC.; CIVITAS THERAPEUTICS, INC.; NEURONEX, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 038950/0436 →
ASSIGNMENT AND RELEASE OF SECURITY INTEREST Recorded Jul 10, 2013
From: HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
To: NEUROGESX, INC.
Reel/Frame 030777/0782 →
SECURITY AGREEMENT Recorded Nov 13, 2012
From: NEUROGESX, INC.
To: HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
Reel/Frame 029291/0807 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2006
From: JAMIESON, GENE C.; MUHAMMAD, NAWEED; BLEY, KEITH R.
To: NEUROGESX, INC.
Reel/Frame 017827/0386 →